Catheter Precision, Inc. (VTAK): debt financing — Catheter Precision acquires heart failure device assets; Q1 revenue up 73% to $142k

Catheter Precision, Inc.

Subsidiary Cardionomix buys patents/trademarks for Cardionomic's CPNS System (acute decompensated heart failure).
Purchase price: 1M restricted VTAK shares plus a $1.5M promissory note (4% interest, 3-year maturity).
Closing conditions include NYSE American listing approval; deal must close by July 21, 2025.
Preliminary Q1 2025 revenue $142k vs $82k YoY (+73%).
Company warns it needs additional financing to develop assets; dilution expected.

item 1.01 item 2.03 item 2.01 item 2.02 item 8.01 item 3.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.95

Catheter Precision, Inc. incurred loan of $1.5 million with Cardionomic (assignment for the benefit of creditors), LLC at 4% per annum maturing three years following issuance.

Instrument: loan
Principal: $1.5 million
Counterparty: Cardionomic (assignment for the benefit of creditors), LLC
Rate: 4% per annum
Maturity: three years following issuance
Event: incurrence

Exact text from the filing

the issuance by Cardionomix of a promissory note (the "Note") in the amount of $1.5 million, with simple interest accruing at 4% per annum on the principal thereof and no interest or principal payable until the maturity date of the Note, which will be three years following issuance of the Note.

View on SEC.gov

101 debt financings filed in the last 30 days. Browse all debt financings →

Catheter Precision, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-25-012731

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.